首页 » 文章 » 文章详细信息
International Journal of Hypertension Volume 2019 ,2019-07-02
Feasibility of Screening Primary Aldosteronism by Aldosterone-to-Direct Renin Concentration Ratio Derived from Chemiluminescent Immunoassay Measurement: Diagnostic Accuracy and Cutoff Value
Research Article
Tianqi Li 1 Yeshuo Ma 2 Ying Zhang 1 Yue Liu 3 Tingting Fu 4 Ri Zhang 1 Kai Kang 1 Yingchao Yang 1 Lixin Wang 1 Yinong Jiang 1 Yan Lu 1
Show affiliations
DOI:10.1155/2019/2195796
Received 2018-10-22, accepted for publication 2019-06-13, Published 2019-06-13
PDF
摘要

Objectives. Aldosterone-to-plasma renin activity ratio (ARR) derived from traditional radioimmunoassay (RIA) is widely used to detect primary aldosteronism (PA). Recently, aldosterone-to-direct renin concentration ratio (ADRR), which is calculated by direct renin concentration (DRC) measured by chemiluminescent immunoassay (CLIA), is proposed to replace ARR as the screening test method for PA. The purpose of the present study was to estimate the diagnostic accuracy and cutoff value of ADRR as screening test for PA. Methods. 450 hypertensive patients with suspected PA referred to hypertension center of our department were enrolled and underwent screening and confirmatory tests of PA. Plasma renin activity (PRA), DRC, and plasma aldosterone concentration (PAC) were measured by both RIA and CLIA simultaneously during screening and confirmatory test. Results. 386 patients were diagnosed as primary hypertension (PH) and 64 patients as PA. Within-patient correlation between PRA and DRC (r=0.88, P<0.001) and correlation between PAC measured by RIA and CLIA were high (r=0.80, P<0.001). The optimal cutoff value of ADRR was 2.93 (ng/dL)/(mU/L), sensitivity 80.33%, and specificity 92.11%. The optimal cutoff value of ARR was 25.28 (ng/dL)/(ng/mL/h), sensitivity 76.92%, and specificity 93.38%. Conclusion. The optimal cutoff values of ADRR and ARR for screening PA are defined in this patient cohort with high sensitivity and specificity. Our results are of clinical importance for accelerating the extensive use of ADRR as a screening test for PA in daily practice.

授权许可

Copyright © 2019 Tianqi Li et al. 2019
This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

通讯作者

1. Yinong Jiang.Department of Cardiology, Institute of Cardiovascular Diseases, First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China, dlmedu.edu.cn.yinongjiang@126.com
2. Yan Lu.Department of Cardiology, Institute of Cardiovascular Diseases, First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China, dlmedu.edu.cn.yan_lu439@126.com

推荐引用方式

Tianqi Li,Yeshuo Ma,Ying Zhang,Yue Liu,Tingting Fu,Ri Zhang,Kai Kang,Yingchao Yang,Lixin Wang,Yinong Jiang,Yan Lu. Feasibility of Screening Primary Aldosteronism by Aldosterone-to-Direct Renin Concentration Ratio Derived from Chemiluminescent Immunoassay Measurement: Diagnostic Accuracy and Cutoff Value. International Journal of Hypertension ,Vol.2019(2019)

您觉得这篇文章对您有帮助吗?
分享和收藏
0

是否收藏?

参考文献
[1] C. A. Dorrian, B. J. Toole, S. Alvarez-Madrazo, A. Kelly. et al.(2010). A screening procedure for primary aldosteronism based on the Diasorin Liaison(R) automated chemiluminescent immunoassay for direct renin. Annals of Clinical Biochemistry.47(3):195-199. DOI: 10.1093/ajh/hpy018.
[2] A. Hannemann, H. Wallaschofski. (2012). Prevalence of primary aldosteronism in patient's cohorts and in population-based studies - a review of the current literature. Hormone and Metabolic Research.44(3):157-162. DOI: 10.1093/ajh/hpy018.
[3] F. Pizzolo, G. Salvagno, B. Caruso, C. Cocco. et al.(2017). Fully automated chemiluminescence vs RIA aldosterone assay in primary aldosteronism work-up. Journal of Human Hypertension.31(12):826-830. DOI: 10.1093/ajh/hpy018.
[4] G. P. Rossi, M. Barisa, A. Belfiore, G. Desideri. et al.(2010). The aldosterone-renin ratio based on the plasma renin activity and the direct renin assay for diagnosing aldosterone-producing adenoma. Journal of Hypertension.28(9):1892-1899. DOI: 10.1093/ajh/hpy018.
[5] W. Gan, W. Lin, J. Ouyang. (2018). High efficiency of the aldosterone-to-renin ratio in precisely detecting primary aldosteronism. Journal of Human Hypertension.21. DOI: 10.1093/ajh/hpy018.
[6] M. Varano, P. Iacono, M. M. Tedeschi, C. Letizia. et al.(2017). Comparisons of microvascular and macrovascular changes in aldosteronism-related hypertension and essential hypertension. Scientific Reports.7(1):2666. DOI: 10.1093/ajh/hpy018.
[7] P. Glinicki, W. Jeske, L. Bednarek-Papierska, A. Kruszyńska. et al.(2015). The ratios of aldosterone/plasma renin activity (ARR) versus aldosterone / direct renin concentration (ADRR). Journal of the Renin-Angiotensin-Aldosterone System.16(4):1298-1305. DOI: 10.1093/ajh/hpy018.
[8] J. Burrello, S. Monticone, F. Buffolo, M. Lucchiari. et al.(2016). Diagnostic accuracy of aldosterone and renin measurement by chemiluminescent immunoassay and radioimmunoassay in primary aldosteronism. Journal of Hypertension.34(5):920-927. DOI: 10.1093/ajh/hpy018.
[9] L. Deng, Z. Xiong, H. Li, X. Lei. et al.(2018). Analytical validation and investigation on reference intervals of aldosterone and renin in Chinese Han population by using fully automated chemiluminescence immunoassays. Clinical Biochemistry.56:89-94. DOI: 10.1093/ajh/hpy018.
[10] W. F. Young Jr.. (2019). Diagnosis and treatment of primary aldosteronism: practical clinical perspectives. Journal of Internal Medicine.285(2):126-148. DOI: 10.1093/ajh/hpy018.
[11] S. Monticone, A. Viola, D. Tizzani, V. Crudo. et al.(2012). Primary aldosteronism: who should be screened?. Hormone and Metabolic Research.44(3):163-169. DOI: 10.1093/ajh/hpy018.
[12] C. Lonati, N. Bassani, A. Gritti, E. Biganzoli. et al.(2014). Measurement of plasma renin concentration instead of plasma renin activity decreases the positive aldosterone-to-renin ratio tests in treated patients with essential hypertension. Journal of Hypertension.32(3):627-634. DOI: 10.1093/ajh/hpy018.
[13] R. Morimoto, Y. Ono, Y. Tezuka, M. Kudo. et al.(2017). Rapid screening of primary aldosteronism by a novel chemiluminescent immunoassay. Hypertension.70(2):334-341. DOI: 10.1093/ajh/hpy018.
[14] J. W. Funder, R. M. Carey, C. Fardella, C. E. Gomez-Sanchez. et al.(2008). Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism.93(9):3266-3281. DOI: 10.1093/ajh/hpy018.
[15] G. P. Rossi, G. Ceolotto, G. Rossitto, T. M. Seccia. et al.(2016). Prospective validation of an automated chemiluminescence-based assay of renin and aldosterone for the work-up of arterial hypertension. Clinical Chemistry and Laboratory Medicine (CCLM).54(9):1441-1450. DOI: 10.1093/ajh/hpy018.
[16] S. Monticone, J. Burrello, D. Tizzani, C. Bertello. et al.(2017). Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice. Journal of the American College of Cardiology.69(14):1811-1820. DOI: 10.1093/ajh/hpy018.
[17] R. Morimoto, K. Omata, S. Ito, F. Satoh. et al.(2018). Progress in the management of primary aldosteronism. American Journal of Hypertension.31(5):522-531. DOI: 10.1093/ajh/hpy018.
[18] J. W. Funder, R. M. Carey, F. Mantero, M. H. Murad. et al.(2016). The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism.101(5):1889-1916. DOI: 10.1093/ajh/hpy018.
[19] G. P. Rossi, G. Bernini, C. Caliumi, G. Desideri. et al.(2006). A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. Journal of the American College of Cardiology.48(11):2293-2300. DOI: 10.1093/ajh/hpy018.
[20] S. Monticone, F. D'Ascenzo, C. Moretti, T. A. Williams. et al.(2018). Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. The Lancet Diabetes & Endocrinology.6(1):41-50. DOI: 10.1093/ajh/hpy018.
文献评价指标
浏览 2次
下载全文 0次
评分次数 0次
用户评分 0.0分
分享 0次